We have so far concluded license agreements with more than 170 entities worldwide including major pharmaceutical companies.(as of September 2017)
Some of our licensees
Pharmaceutical companies and Reagents amount to nearly 50%. Thus, the expansion of iPS cell technology in bio-industry is currently prominent, and the iPS cell technology will further expand since new participants from research instrument manufacture are increasing.